For Investors


2017 was an important year of transition for RepliCel shareholders. The company delivered its first complete set of phase 1 human clinical data, the first fully functional prototypes of its dermal injector, and a second major international co-development and licensing partnership in Asia.

2019 is expected to deliver more partnership announcements, the launch of next phase clinical trials, and see RepliCel transition into steady revenue generation as the company prepares for the first the commercial launch of one of its products.

Here you can keep up-to-date with our share price, upcoming events, and latest presentations. We invite you to sign up for our email alerts and welcome any questions you may have.

Last N/A
Change N/A
Change % N/A
Open N/A
52 Week Low N/A
52 Week High N/A
Volume N/A
  • 1 mo
  • 3 mo
  • 6 mo
  • 1 yr
  • 2 yr
  • 5 yr

REPCF Market Data

Corporate Name
RepliCel Life Sciences. 
Exchange/Symbol  OTCQB/REPCF 
Exchange/Symbol  TSXV/RP 
Shares Issued
Shares Issued on a Fully Diluted Basis  33,393,036
Insider Ownership  21% 
CUSIP #  76027P103 
ISIN #  CA 76027P1036 
Fiscal Year End  December 31 
Date of Incorporation  1967 
Incorporated  British Columbia, Canada 
Industry  Life Sciences 
Transfer Agent  Computershare 
Corporate Attorneys  Clark Wilson LLP 
Auditors  BDO Canada LLP  



These stock quotes and related data are provided for information purposes only and are not intended for trading purposes. RepliCel Life Sciences Inc. will not be liable for any inaccuracies or delays in such data, or for any actions taken in reliance thereon. Potential investors should seek independent information and advice from qualified investment professionals prior to investment.